{"id":35489,"date":"2026-03-20T07:12:10","date_gmt":"2026-03-20T07:12:10","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/35489\/"},"modified":"2026-03-20T07:12:10","modified_gmt":"2026-03-20T07:12:10","slug":"novartis-bold-move-acquiring-potential-game-changer-in-breast-cancer-treatment","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/35489\/","title":{"rendered":"Novartis&#8217; Bold Move: Acquiring Potential Game-Changer in Breast Cancer Treatment"},"content":{"rendered":"<p>&#13;<\/p>\n<p>In a significant move within the pharmaceutical sector, Novartis has struck a deal to acquire SNV4818, a pioneering breast cancer drug candidate, from Synnovation Therapeutics. The agreement comprises an initial payment of $2 billion, with a potential $1 billion in further contingent payments based on future development achievements.<\/p>\n<p>SNV4818 is part of the emerging class of selective PI3K\u03b1 inhibitors, representing a novel approach to treating HR positive\/HER2 negative breast cancer, a prevalent form of the disease. This acquisition underscores Novartis&#8217; commitment to expanding its oncology portfolio and exploring new therapeutic areas.<\/p>\n<p>The drug candidate not only targets a specific type of breast cancer but also holds promise for application in treating other solid tumors, marking a potentially transformative step in cancer treatment. Novartis&#8217; strategic acquisition highlights the growing emphasis on innovative research and targeted drug development in the fight against cancer.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; In a significant move within the pharmaceutical sector, Novartis has struck a deal to acquire SNV4818, a&hellip;\n","protected":false},"author":2,"featured_media":35490,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[3264,207,4655,21018,206,337,21017,21015,21016,13414],"class_list":{"0":"post-35489","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-acquisition","9":"tag-breast-cancer","10":"tag-her2-negative","11":"tag-hr-positive","12":"tag-novartis","13":"tag-pharmaceuticals","14":"tag-pi3k-inhibitors","15":"tag-snv4818","16":"tag-synnovation-therapeutics","17":"tag-tumors"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116260263862427739","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=35489"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/35489\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/35490"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=35489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=35489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=35489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}